The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 02, 2025 for Aayush Agrawal, trustee ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajanta Pharma informed the exchanges that it received a disclosure under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, dated July 02, 2025. The disclosure was filed by Aayush Agrawal, described as a trustee, indicating a reporting obligation triggered by shareholding or voting rights crossing or changing from certain thresholds. Details regarding the nature of the change (acquisition or disposal) and the exact shareholding figures are not fully visible in the available headline. Such filings are routine compliance disclosures required from significant shareholders, including those linked to the promoter group.
At the headline level, this appears to be a routine regulatory disclosure by a promoter-group entity (trustee), with no immediate signal of a material stake change. Shareholders should look for the detailed filing to understand if shares were bought, sold, or if the disclosure relates to a change in the nature of existing holdings.